Last reviewed · How we verify
EU Avastin®
Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth.
Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with chemotherapy).
At a glance
| Generic name | EU Avastin® |
|---|---|
| Sponsor | Bio-Thera Solutions |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits angiogenesis—the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, the drug reduces tumor progression and improves survival in combination with chemotherapy or other targeted agents.
Approved indications
- Metastatic colorectal cancer (in combination with chemotherapy)
- Metastatic non-small cell lung cancer (in combination with chemotherapy)
- Metastatic breast cancer (in combination with chemotherapy)
- Glioblastoma (recurrent)
- Metastatic renal cell carcinoma (in combination with interferon-alpha)
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage (all grades)
- Thromboembolism
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
- Diarrhea
Key clinical trials
- A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers (PHASE1)
- To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects (PHASE1)
- Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers (PHASE1)
- TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer (PHASE3)
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects (PHASE1)
- Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers (PHASE1)
- A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer (PHASE3)
- A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EU Avastin® CI brief — competitive landscape report
- EU Avastin® updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI